Cancer Therapy Due to Apoptosis: Galectin-9

Koji Fujita 1, Hisakazu Iwama 2, Kyoko Oura 1, Tomoko Tadokoro 1, Eri Samukawa 1, Teppei Sakamoto 1, Takako Nomura 1, Joji Tani 1, Hirohito Yoneyama 1, Asahiro Morishita 1, Takashi Himoto 3, Mitsuomi Hirashima 4 and Tsutomu Masaki 1,*

1 Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Ikenobe 1750-1, Miki, Kita, Kagawa 761-0793, Japan; 92m7v9@med.kagawa-u.ac.jp (K.F.); oura@med.kagawa-u.ac.jp (K.O.); tadokoro@med.kagawa-u.ac.jp (T.T.); samukawa@med.kagawa-u.ac.jp (E.S.); sakamoto@med.kagawa-u.ac.jp (T.S.); nomura@med.kagawa-u.ac.jp (T.N.); tani@med.kagawa-u.ac.jp (J.T.); yoneyama@med.kagawa-u.ac.jp (H.Y.); morishita@med.kagawa-u.ac.jp (A.M.)

2 Life Science Research Center, Kagawa University, Ikenobe 1750-1, Miki, Kita, Kagawa 761-0793, Japan; iwama@med.kagawa-u.ac.jp

3 Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Hara 281-1, Mure, Takamatsu, Kagawa 761-0123, Japan; himoto@chs.pref.kagawa.jp

4 Department of Immunology and Immunopathology, Faculty of Medicine, Kagawa University, Ikenobe 1750-1, Miki, Kita, Kagawa 761-0793, Japan; mitsuomi@kms.ac.jp

* Correspondence: tmasaki@med.kagawa-u.ac.jp; Tel.: +81-87-891-2156

Academic Editor: Anthony Lemarié

Received: 22 September 2016; Accepted: 27 December 2016; Published: 1 January 2017

Abstract: Dysregulation of apoptosis is a major hallmark in cancer biology that might equip tumors with a higher malignant potential and chemoresistance. The anti-cancer activities of lectin, defined as a carbohydrate-binding protein that is not an enzyme or antibody, have been investigated for over a century. Recently, galectin-9, which has two distinct carbohydrate recognition domains connected by a linker peptide, was noted to induce apoptosis in thymocytes and immune cells. The apoptosis of these cells contributes to the development and regulation of acquired immunity. Furthermore, human recombinant galectin-9, hG9NC (null), which lacks an entire region of the linker peptide, was designed to resist proteolysis. The hG9NC (null) has demonstrated anti-cancer activities, including inducing apoptosis in hematological, dermatological and gastrointestinal malignancies. In this review, the molecular characteristics, history and apoptosis-inducing potential of galectin-9 are described.

Keywords: galectin-9; glycan; apoptosis; pyroptosis; caspase-1; cancer; therapy

1. Introduction

Physiologic tissue development and normal kinetics of mature tissues depend on apoptosis to remove excess or abnormal cells from normal tissue. These processes allow the tissue to maintain its normal morphological quantity and physiological quality [1]. Abrogation of apoptosis results in an imbalance of mitosis and cell death in the tissue, disturbing tissue homeostasis, while accumulating functionally impaired cells that cannot undergo apoptosis. The accumulation of excess cells causes hyperplasia and the increase of functionally dysregulated cells, which might also be genetically impaired, contributes to carcinogenesis [2]. A series of studies prior to the proposal of “apoptosis” in the 1970s analyzed the contribution of mitosis and cell death to the tumor doubling time, reporting that cell death appears to determine tumor growth more so than mitosis [3–5].

Lectin, defined as “a carbohydrate-binding protein that is not an enzyme or antibody”, has been the subject of research on anti-cancer agents for nearly a century. In fact, lectin can affect cell fate, as expected from the variety of lectin types in animal, their wide distribution in various tissues and differential expression from embryonic cells to malignant cells [6]. Soluble endogenous lectins,
represented by galectins among animal lectins, interact extracellularly with cell surface glycoconjugates and transmit signals that potentially determine cell fate. On the other hand, intracellular lectins that are located in plasma membranes modulate such signals by regulating receptor-ligand interactions, receptor trafficking and endocytosis [7–10].

Among diverse animal lectins, galectin-9, the ninth member of the β-galactoside-binding soluble lectin family, was independently cloned by four groups in 1997 [11–14]. Galectin-9, which is expressed on thymocyte surfaces, has been revealed to induce T lymphocyte apoptosis in thymic negative selection of T cells, playing a pivotal role in the development of the acquired immune system [12]. Furthermore, subsequent studies clarified that the administration of exogenous galectin-9 induced apoptosis of human malignant cells and immune responsible cells in vitro and in vivo, suggesting that galectin-9 can be a candidate anti-cancer agent based on the carbohydrate recognition function of this animal lectin [15,16]. In this review, malignant cell apoptosis and galectin-9 are reviewed and the potential for galectin-9 to be an anti-cancer agent is presented.

2. Apoptosis and Malignancy

2.1. Apoptosis, a Type of Programmed Cell Death

The idea of programmed cell death was first proposed in 1972 based on morphological profiling and differentiation from necrosis [1]. Apoptosis, a type of programmed cell death, is characterized by cytoplasmic cell shrinkage, chromatin condensation and DNA fragmentation, and segmentation into apoptotic bodies (called blebbing) and occurs in response to extrinsic and intrinsic stimuli [17]. The plasma membrane is kept intact in apoptosis, preventing inflammation and tissue injury that would otherwise occur in response to cytokine release from dying cells.

Apoptosis, which was first defined by morphological investigations, has been further investigated in terms of the associated biochemical aspects [18]. Two protein families, the caspase and Bcl-2 families, play crucial roles in executing or halting apoptosis. Caspases are cysteine-dependent, aspartate-specific peptidases, which initiate or affect apoptotic and inflammatory pathways. In humans, a total of 11 caspases, the 1st to 10th and 14th, have been cloned [19]. The Bcl-2 protein family shares homology domains between members. Bcl-2 and its relatives have four domains, BH1-4. They are divided into two subfamilies; anti-apoptotic proteins represented by Bcl-2 are Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1 and Bcl-B and pro-apoptotic proteins are Bax and Bak. Other Bcl-2-relatives, BH3-only proteins, have a single homology domain (BH3) [20]. BH3-only proteins include at least eight members: Bik, Bad, Bir, Bmf, Hrk, Noxa and Puma. BH3-only proteins have pro-apoptotic effects by interfering with anti-apoptotic Bcl-2 relatives or directly stimulating pro-apoptotic Bax and Bak [21,22].

Apoptosis is classified into two subtypes according to the biochemical machineries: extrinsic and intrinsic, as shown in Figure 1. The extrinsic apoptotic mechanism is activated by the interaction between death receptors on the cell surface and their ligands [23]. The combination of death receptor-ligands is represented by Tumor Necrosis Factor (TNF) Receptor-1-TNFα, FAS-Fas Ligand (FasL), TNF-related apoptosis-inducing ligand (TRAIL) Receptor-1 and -2-TRAIL. Death receptors share a structural feature in their intracellular components, called the death domain. Upon stimulation, death domains enable death receptors to form an oligomer and change conformation. Then, death receptors and adapter proteins, such as Fas-Associated protein with Death domain (FADD) and TNF Receptor-1 associated Death Domain protein (TRADD), construct a complex called death-inducing signaling complex (DISC), which activates initiator pro-caspase-8/10 [24].

The intrinsic apoptotic pathway is characterized by mitochondrial change in response to various stress signals, such as severe genetic damage, hypoxia and oxidative stress, which activate the initiator pro-caspase-9 [25]. Mitochondrial pro-apoptotic proteins, BH3-only members, antagonize anti-apoptotic proteins, Bcl-2, Bcl-xL and Mcl-1. Subsequently, the mitochondrial outer membrane is disrupted, and its permeability increases, resulting in cytochrome-c leakage into the cytosol [26].
Cytochrome-c in cytosol forms a complex with Apaf-1, called the apoptosome, which assists in auto-activation of initiator pro-caspase-9.

Figure 1. Two major pathways of apoptosis. Extrinsic pathway is induced by death ligand-death receptor interaction. Oligomerized death receptors form death inducing signaling complex (DISC). DISC activates initiator pro-caspase-8/10. Intrinsic pathway is initiated by Bcl-2 family members. Pro-apoptotic proteins, Bax and Bak, lead mitochondrial outer membrane permeability (MOMP), resulting leakage of cytochrome-c from mitochondrial inter membrane space into cytosol. Thus, cytochrome-c constructs apoptosome with Apaf-1 and activates initiator pro-caspase-9. Caspase-8 in extrinsic apoptotic cascades cleaves Bid into tBid, which recruits intrinsic apoptotic response.

Extrinsic and intrinsic apoptosis share the executor caspase-3/6/7, which cleave critical cellular components and induce cell death [27]. Extrinsic apoptotic cascades recruit the intrinsic pathway via one BH3-only protein, Bid, when the cell does not die from death receptor-ligand interaction alone [2]. Caspase-8 is subsequently activated through death receptor-ligand interactions and cleaves Bid, generating a tBid fragment, resulting in mitochondrial outer membrane permeability (MOMP) in the intrinsic pathway.

2.2. Evasion of Apoptosis: A Hallmark of Cancer

In general, malignant tissues are characterized by six cell biology features as follows: (1) self-sufficiency in growth signals; (2) insensitivity to growth-inhibitory signals; (3) evasion of cell death; (4) limitless replication potential; (5) sustained angiogenesis; and 6. tissue invasion and metastasis [28]. In combination with other cancer hallmarks described above, evasion of apoptosis affects tumor growth kinetics through decreasing the elimination of DNA-damaged cells, resulting in aberrant cellular proliferation [1]. Furthermore, dysregulation of apoptotic machineries provides the basis for tumor cell chemoresistance [21,29]. Therefore, apoptosis promotion is an essential anti-cancer strategy in addition to the suppression of cancer cell mitosis.

2.3. Glycans Differentiate Apoptotic Signals and Affect Cell Fate

Cell surface receptors which commit to apoptotic process are glycosylated. Protein glycosylation alters protein structure, conformation and function [30]. The glycan structure is diversified by 10 monosaccharide species that combine to generate a glycan according to differences in the linkages, aromatic status, branching, lengths and substituted components [31]. Glycan-protein binding also creates a variety of glycoconjugates. A glycan can covalently bind to at least nine amino
Two representative linkages are N-glycosylation binding to asparagine residues and O-glycosylation to serine/threonine residues [32,33]. Proteomic information is thus modulated and diversified by exponentially differentiated structure of glycoconjugates, that is, glycome. Different from DNA synthesis, RNA transcription or Protein translation, glycan lacks DNA template. Otherwise, glycosylation is influenced by non template factors such as carbohydrate substrates availability, activity and expression level of enzymes and transporters [34].

Aberrant glycosylation of death receptors alters apoptotic pathways, modifying cell fate. For example, two N-glycosylation sites on the Fas ligand stabilize the extrinsic apoptotic machinery DISC [35]. The stability of DISC, DISC-DISC interactions and pro-caspase-8 oligomerization are important to the initiation of extrinsic apoptosis. If Fas ligands are aberrantly glycosylated, Fas does not oligomerize or induce apoptosis [36]. For TRAIL Receptor-1 and -2, which have two potential O-glycosylation sites, fucosylation of core-2 O-glycans increases the sensitivity of cancer cells to TRAIL-induced apoptosis [37,38]. Thus, glycosylation of molecules that are pivotal to initiating apoptosis might modulate apoptotic signal transduction by strengthening or weakening the affinity of receptors for their ligands.

2.4. Lectins Regulate Diverse Information on Glycoconjugates

With consideration for the role of glycosylation on apoptotic machinery, lectin as a glycan ligand can regulate apoptotic pathways and modulate cell fates [39]. Lectin, glycan-binding proteins, multivalently interact with glycosylated death receptors, which might alter the affinity of pro-apoptotic molecules for their ligands [40–42]. Lectin in the plasma membrane forms lattice structures by binding to and bridging between glycoconjugates. The lattice structure might help anchor receptors on the cell surface, assigning a proper location for the receptors on the cell surface and halting receptor turnover [43].

The galectin family is a group of β-galactoside-specific soluble animal lectins that share highly conserved sequences of carbohydrate recognition sites. Recent studies have revealed that galectin members can promote or suppress apoptotic pathways, which contributes to acquired immunity through the negative selection of T lymphocytes in the thymus [12]. Endogenous galectins also orchestrate and play pivotal roles in tumor progression, in which some galectins are upregulated, and others are downregulated [44]. Furthermore, one of recombinant-type human galectin-9, hG9NC (null), which has greater protease-resistant properties than endogenous original molecules, has demonstrated anti-cancer activity, inducing apoptosis on epithelial cancer species and hematological malignancies.

3. Identification of Galectin-9

Galectin-9, a 36-kDa β-D-galactoside mammalian lectin, was identified from murine embryonic kidney and human Hodgkin’s lymphoma tissues in 1997 [11,12]. The galectin exhibited specific affinity to the lactosyl group and had two distinct carbohydrate recognition domains in the N-terminus and C-terminus. The two domains were connected by a linker peptide, such as galectin-4, -6 and -8, which are tandem repeat-type peptides. The linker peptide length varied among the galectins and yielded three isoforms (Figure 2). This galectin was called galectin-9. The existence and characteristics of galectin-9 have been investigated since 1991. ConA-activated CD4− T lymphocytes produced eosinophil chemoattractants, called ecalectin, which has a molecular weight of 30–40 kDa; no hydrophobic signaling peptides had to be secreted outside the cells [45,46]. Although ecalectin was first considered a variant of galectin-9 because the difference in the sequence was limited to only 4 amino acids, it was later found to be identical to the medium-sized isoform of galectin-9, and the difference in the sequence was attributed to sequencing errors [14,47]. The urate transporter was also cloned and found to be identical to galectin-9 in humans and in mice [13,48]. Amino acid sequencing of the urate transporter revealed no differences from long isoform of galectin-9. Four amino acid differences that were caused by 4 nucleotide differences between the human urate transporter and galectin-9 (Genbank accession number Z49107) were attributed to sequencing errors in galectin-9.
Whether the two galectin-9-like molecules are expressed and active remains controversial. Galectin-9, which consists of 11 exons, yielding a 355-amino acid-length product [9]. So-called galectin-9 (F1-F5) protein, which has several isoforms, is presumed to be transcribed from the genetic location, LGALS9. On the 17q11.2, two transcripts that are almost identical to the nucleotide sequence galectin-9, LGALS9B (HGNC:24842) and LGALS9C (HGNC:33874), are encoded, indicating gene duplication. Whether the two galectin-9-like molecules are expressed and active remains controversial.

4. Molecular Profiling of Galectin-9

4.1. Genomic Localization and Expression

The galectin-9 gene LGALS9 is encoded on the short arm of chromosome 17, 17q11.2 (HGNC:6570), which consists of 11 exons, yielding a 355-amino acid-length product [9]. So-called galectin-9 protein, which has several isoforms, is presumed to be transcribed from the genetic location, LGALS9. On the 17q11.2, two transcripts that are almost identical to the nucleotide sequence galectin-9, LGALS9B (HGNC:24842) and LGALS9C (HGNC:33874), are encoded, indicating gene duplication. Whether the two galectin-9-like molecules are expressed and active remains controversial.

4.2. Structure

Galectin-9 is classified as a tandem-repeat type galectin, which consists of two distinct β-galactoside-binding sites linked by a peptide [12]. The N-terminal carbohydrate recognition domain (CRD) of 148 amino acids shares 39% of its sequence with the C-terminal CRD of 149 amino acids [11]. X-ray crystallography indicated that N-CRD is formed by six-stranded (S1–S6) and five-stranded (CRD) of 148 amino acids shares 39% of its sequence with the C-terminal CRD of 149 amino acids [11]. The galectin-9 gene LGALS9 is encoded on the short arm of chromosome 17, 17q11.2 (HGNC:6570), which consists of 11 exons, yielding a 355-amino acid-length product [9]. So-called galectin-9 protein, which has several isoforms, is presumed to be transcribed from the genetic location, LGALS9. On the 17q11.2, two transcripts that are almost identical to the nucleotide sequence galectin-9, LGALS9B (HGNC:24842) and LGALS9C (HGNC:33874), are encoded, indicating gene duplication. Whether the two galectin-9-like molecules are expressed and active remains controversial.

Linker peptides flexibly connect two distinct carbohydrate recognition domains. The CRDs are able to rotate and thus have potential to constitute more diverse glycan-galectin-9 complexes. Galectin-9 has protease-sensitive sites in linker peptides and is cleaved into two monovalent sugar-specific proteins that are similar to the galectin prototype [53].

Galectin-9 has three classical isoforms, according to different lengths of a flexible linker peptide, as a result of posttranscriptional splicing (Figure 2). The linker peptide of 58 amino acids represents the long-sized isoform (gal-9L or gal-9FL). The linker peptides with 26 and 14 amino acids represent medium-sized (gal-9M) and short-sized (gal-9S) galectin-9 [54]. The medium-sized galectin-9 lacks exon 5 (gal-9Δ5) and short-formed galectin-9 lacks exons 5 and 6 (gal-9Δ5/6). These linker peptides were not essential in some CRD-dependent physiologic actions, such as in the chemoattraction of eosinophils and the induction of T-lymphocyte apoptosis because even a recombinant galectin-9 that...
Int. J. Mol. Sci. 2017, 18, 74
6 of 15

lacks a linker peptide had similar activities [53–55]. On the other hand, the linker peptide length can affect the structure of galectin-9-sugar oligomerization and lattice formation on the cell surface [56]. Furthermore, other splice variants that involve deletion of exon 10 transcripts have been reported in human samples [48,57,58]. Deletion of exon 10 transcripts from mature galectin-9 messenger RNA results in truncation of C-CRD, which is encoded on exon 11 [9]. C-CRD truncation directly affects the carbohydrate specificity of galectin-9 in each isoform. Functional diversity of galectin-9 isoforms according to the linker peptide length and C-CRD truncation has yet to be elucidated.

4.3. Secretion and Solubility

The secretion mechanisms of galectin members have not been well established, in part because galectins, including galectin-9, lack hydrophobic signal peptides that can enter the endoplasmic reticulum (ER) and be secreted outside cells via the classical secretion pathway [59]. While up to 50% of galectin-9 is recovered with the soluble elements of cytoplasm and another fraction with the cell surface membrane and nucleus, some evidence has clarified that galectin-9 is released from cells via the non-classical pathway, including the exosome. For example, the Jurkat T cell line that expressed galectin-9 on its cell surface released eosinophil chemoattractants, including medium- and long-sized galectin-9 isoforms, when antigens stimulated the T cells [60]. Murine CD4+ T cells expressing galectin-9 on their cell surface secreted soluble galectin-9, which increased upon TCR stimuli [61]. Exosomes containing galectin-9 were released from EBV-infected nasopharyngeal carcinoma cells into culture media [62,63].

4.4. Carbohydrate Specificity

Galectin-9 presents striking affinity for branched N-glycans and repeated oligolactosamines [64]. The affinity of this galectin for N-glycans depends on the glycan valency, with triantennary N-glycans interacting with galectin-9 more tightly than the biantennary N-glycans, and the biantennary N-glycans binding more tightly than the monovalent N-glycans. The affinity for oligolactosamines is also drastically enhanced when the repeat number is larger. In addition, the affinity for N-glycans and oligolactosamines is shared by N-CRD and C-CRD. Differential specificity of the two distinct CRD to glycoconjugates is also determined. N-CRD, not C-CRD, binds to Forssman pentasaccharide, A-hexasaccharide and several glycolipid-type glycans. Comprehensive data of galectin-9’s ligands are available in data repositories at Consortium for Functional Glycomics (http://www.functionalglycomics.org/).

4.5. Bivalency, Cross-Linking and Lattice Formation

Galectin-9, a tandem-repeat type of galectin, shows bivalency and can cross-link two glycoconjugates. Thus, galectin-9 is able to execute cell to cell adhesion and cell to matrix interaction, contributing to physiologic tissue functions and pathologic responses. On cell surface, galectin-9 might cluster cell surface receptors and modulate strength and duration of signaling (Figure 3). When the glycoconjugates have bi- or multivalent potential to bind to lectins, galectin-9 and its binding partners can form a two- or three-dimensional lattice structure, as shown in Figure 4 [65]. The galectin-9-glycan lattice provides higher diversity based on the differences in the binding partners for two distinct CRDs and the rotational freedom of the CRDs that is allowed by flexible linker peptides. In general, lectin-glycan lattices are constructed by multiple low-affinity interactions and are thus diverse based on differential glycosylation of proteins or lectin expression levels [66]. The galectin-glycan lattices could perform three major roles in cell biology, including organizing cell membrane domains, determining thresholds of cell signaling and restricting the receptor residency time on the cell surface [67]. The function of lattice formation specific to galectin-9 has yet to be investigated, while that of galectin-1-glycan lattices has been well established [56,68,69].
To be specific to the cell type, this lectin is dominantly detected in leukocytes that are responsible for cervical cancer [77] and skin cancer [78,79]. Galectin-9 expression is enhanced in comparison to that of normal adjacent tissues in oral cancer [80], pancreatic cancer [81], and hematologic malignancies.

Cell surface is reportedly decreased [75] as with other solid tumors, such as prostate cancer [76], stimulated by IFN [74].

To be specific to the cell type, this lectin is dominantly detected in leukocytes that are responsible for innate and acquired immunity [71], thymocytes [70], activated endothelial cells [72,73] and fibroblasts.

Galectin-9 distributes among tissues, such as in the liver, small intestine, thymus, kidney, spleen, lung, cardiac and skeletal muscle [70], brain [13], placenta, pancreas, prostate and colon [48]. To be specific to malignant tissues, galectin-9 expression on the hepatocellular carcinoma (HCC) cell surface is reportedly decreased [75] as with other solid tumors, such as prostate cancer [76], cervical cancer [77] and skin cancer [78,79]. Galectin-9 expression is enhanced in comparison to that of normal adjacent tissues in oral cancer [80], pancreatic cancer [81], and hematologic malignancies.

4.6. Expression and Distribution

Galectin-9 distributes among tissues, such as in the liver, small intestine, thymus, kidney, spleen, lung, cardiac and skeletal muscle [70], brain [13], placenta, pancreas, prostate and colon [48]. Galectin-9 functions by its divalent sugar binding activity. (a) Cell to extracellular matrix adhesion; (b) Cell to cell adhesion; and (c) Clustering cell surface molecules and modulate their signal delivery.

The galectin-glycan lattices could perform three major roles in cell biology, including organizing cell membrane domains, determining thresholds of cell signaling and restricting the receptor residency time on the cell surface.

The galectin-9-glycan lattice provides higher diversity based on the combination of 10 monosaccharide species on glycoconjugates, different sugar-affinity of galectin-9’s two distinct carbohydrate recognition domains (CRDs) and the rotational freedom of the CRDs that is allowed by flexible linker peptides. The galectin-glycan lattices could perform three major roles in cell biology, including organizing cell membrane domains, determining thresholds of cell signaling and restricting the receptor residency time on the cell surface.

Figure 3. Galectin-9 functions by its divalent sugar binding activity. (a) Cell to extracellular matrix adhesion; (b) Cell to cell adhesion; and (c) Clustering cell surface molecules and modulate their signal delivery.

Figure 4. Lattice formation by galectin-9 and multivalent glycoconjugates. The galectin-9-glycan lattice provides higher diversity based on the combination of 10 monosaccharide species on glycoconjugates, different sugar-affinity of galectin-9’s two distinct carbohydrate recognition domains (CRDs) and the rotational freedom of the CRDs that is allowed by flexible linker peptides. The galectin-glycan lattices could perform three major roles in cell biology, including organizing cell membrane domains, determining thresholds of cell signaling and restricting the receptor residency time on the cell surface.
to that of normal adjacent tissues in oral cancer [80], pancreatic cancer [81], and hematologic malignancies [11]. For gastric cancer, the results seem controversial because the messenger RNA of galectin-9 decreased [82], while the protein expression increased compared with normal mucosa [83].

5. Exogenous Galectin-9 and Apoptosis

5.1. Apoptosis in Thymocytes and Immune Cells

Several full-length clones of recombinant galectin-9 were established from humans and mice and applied on thymocytes and immune cells, such as eosinophils, T lymphocytes, B lymphocytes, and macrophages, which underwent apoptosis [59,70,84,85]. T helper type 1 (T\textsubscript{H1}) cells express a counter receptor for galectin-9, Tim-3, when T cells fully differentiate from naïve cells to T\textsubscript{H1} cells [86]. Galectin-9-Tim-3 interaction leads to mature T\textsubscript{H1} cell apoptosis with intracellular calcium flux and cell aggregation, downregulating T\textsubscript{H1} immunity [85]. Lactose antagonizes binding between galectin-9 and Tim-3, indicating that the galectin-9 stimuli on Tim-3 depend on the interaction between the galectin-9 carbohydrate recognition domain and Tim-3 β-galactoside domain.

CD8\textsuperscript{+} T cells and the CD4\textsuperscript{+} population are susceptible to exogenous galectin-9 stimuli and undergo apoptosis based on the calcium-calpain-caspase-1 pathway [59]. Galectin-9 also induces apoptosis of B cells, which do not express Tim-3 on cell surface. Although apoptosis is executed by the caspase family and three subfamilies of Bcl-2, caspase-1 is plays a more prominent role in pyroptosis than in apoptosis. Pyroptosis definitely differs from apoptosis because pyroptosis evokes inflammation, while apoptosis does not [87,88]. “Pyroptosis” was established in 2001 [89]. This programmed cell death observed in macrophages and dendritic cells is found in infection and inflammatory situations [90,91]. Recent studies have indicated that caspase-1 plays a pivotal role in apoptosis in inflammatory situations [92,93].

5.2. Human Recombinant Galectin-9 without a Linker Peptide, hG9NC(null)

Human recombinant galectin-9 that lacks an entire linker peptide region between the two distinct carbohydrate binding sites, which are the most susceptible in this molecule to proteolysis in sera, was designed and named hG9NC(null), as shown in Figure 2 [53]. A lack of linker peptides decreases the rotational freedom of CRDs, which might limit the lattice formation diversity by this tandem-repeat type of lectin [56]. hG9NC(null) is free from proteolytic cleavage into two monovalent lectins, which might work as antagonists against the CRD-dependent effects of original divalent galectin-9.

5.3. Malignant Cell Apoptosis Induced by the Recombinant Galectin-9 hG9NC(null)

Recombinant galectin-9 induces apoptosis of malignant cells, such as hematologic malignant cells [15,16], malignant melanoma [94] and gastrointestinal tumor species [95–98], in vitro and in vivo. Galectin-9 directly activates apoptotic cell deaths to these cell lines in vitro, not via activation of tumor immunity, demonstrating that the intracellular mechanisms of apoptosis vary depending on cell lines and that apoptosis common pathways have not previously been established [99]. In an in vivo study, galectin-9 modulates tumor immunity and suppresses tumor progression as well as directly binds to cell surface glycans and presents direct apoptotic effects.

For hematologic malignancies, galectin-9 induces the apoptosis of chronic myelogenous leukemia (CML) cells [15] and myeloma cells [16]. For CML cells, galectin-9-dependent apoptosis involves intrinsic apoptotic pathways, inducing ATF3 expression, and does not depend on death receptors. Myeloma cells undergo galectin-9-induced intrinsic apoptosis through JNK and p38 MAP kinase pathways. Apoptosis of CML and myeloma is complicated with endoplasmic reticulum stress. Counter-receptors for galectin-9 on the CML or myeloma cell surface have not been clarified yet. The interaction between galectin-9 and its receptor on myeloma cells likely depends on the carbohydrate-recognition function of this lectin because lactose antagonizes its apoptotic effect (Figure 5).
Several cell lines of malignant melanoma, which does not form colonies when it proliferates, are aggregated and driven to apoptosis [94]. Intracellular pathways, including cell surface receptors for malignant melanoma cell apoptosis, have remained undefined.

Among gastrointestinal cancers, HCC lines have apoptotic responses to galectin-9 stimuli [95]. HCC apoptosis also belongs to intrinsic pathways, including endoplasmic reticulum stress, and it is not affected by death receptors. Tim-3 was not detected on the HCC cell surface, but the genuine receptor should be glycosylated by β-galactoside because lactose suppressed galectin-9-induced apoptosis. Cholangiocellular carcinoma, gallbladder cancer and gastric cancer are subject to galectin-9-induced apoptosis [96–98].

The pharmacokinetics of galectin-9, when subcutaneously and intraperitoneally injected into a mouse, are well established [100]. When 10 µg of galectin-9 was injected into a murine body, the Cmax was 35 ng/mL for subcutaneous injection and 61 ng/mL for intraperitoneal injection, whereas the minimal dose of galectin-9 for demonstrating pharmacological effects was as little as 1 µg/mouse, and no significant side effects were reported. While the physiological median value of galectin-9 in human sera is low-to-undetectable [101], the pharmacokinetics of exogenous galectin-9 in humans remain to be investigated. Additionally, the dose at which this artificial galectin evokes pharmacological effects with or without side effects in humans has yet to be elucidated. In the series of reports described above, the serum concentration of recombinant galectin-9 was determined by ELISA using polyclonal antibodies generated by injection of a recombinant peptide that corresponds to the COOH-terminal domain of the human protein into rabbits [101–104]. The galectin-9 concentration, measured by ELISA, might be affected by antibody clones.

6. Conclusions

Galectin-9 directly induces malignant cell apoptosis, although malignancy partially depends on dysregulation of apoptotic mechanisms. A protease-resistant galectin-9, which lacks a linker peptide, performs apoptotic activities because the interaction between galectin-9 and its receptor depends on the carbohydrate recognition domain of lectin. However, the pharmacological kinetics of galectin-9 in humans have not yet been assessed. According to in vitro work, the cell surface receptor for galectin-9 is the carbohydrate recognition domain of lectin. However, the pharmacological kinetics of galectin-9 in cancer apoptosis has not been identified, and intracellular pathways processed in mammalian cells have not been elucidated. The receptors for galectin-9 lacking a linker peptide, hG9NC (null), in the three malignancies remain unknown.

Figure 5. Human recombinant galectin-9 induces intrinsic apoptosis of cancer involving endoplasmic reticulum. The receptors for galectin-9 lacking a linker peptide, hG9NC (null), in the three malignancies remain unknown.
humans have not yet been assessed. According to in vitro work, the cell surface receptor for galectin-9 in cancer apoptosis has not been identified, and intracellular pathways processed in apoptosis remain to be thoroughly investigated. Galectin-9 has potential as an anti-cancer agent, but these questions should be resolved before drawing major clinical conclusions.

Acknowledgments: There is no financial support to report.

Author Contributions: Koji Fujita wrote “introduction”, the chapter “Exogenous galectin-9 and apoptosis” and conclusion. Kyoko Oura, Tomoko Tadokoro and Eri Samukawa described the chapter “Apoptosis and malignancies”. Teppei Sakamoto, Takako Nomura and Joji Tani wrote the chapter “The history of galectin-9”. Hirohito Yoneyama and Asahiro Morishita described the chapter “Molecular profiling of galectin-9”. Mitsuomi Hirashima reviewed the manuscripts and corrected errors and mistakes in description about glycan and lectin. Takashi Himoto, Hisakazu Iwama and Tsutomu Masaki reviewed the manuscripts and corrected errors and mistakes in description about apoptosis.

Conflicts of Interest: Mitsuomi Hirashima is one of the board members of GalPharma Co., Ltd. The author has the following patents related to material pertinent to this article: “Novel modified galectin 9 proteins and use thereof” which is applied by GalPharma and issued in Japan (4792390), the USA (8,268,324), EPC (1736541), Canada (2,561,696), India (239130), and Korea ((10-1222281) as of 2013.12.2). The author has the following products related to material pertinent to this article: stable-form Gal-9. This does not alter the two authors’ adherence to all the journal policies on sharing data and materials. The other authors declare no conflicts of interest.

References

1. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26, 239–257. [CrossRef] [PubMed]
2. Plati, J.; Bucur, O.; Khosravi-Far, R. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J. Cell. Biochem. 2008, 104, 1124–1149. [CrossRef] [PubMed]
3. Steel, G.G.; Lamerton, L.F. The growth rate of human tumours. Br. J. Cancer 1966, 20, 74–86. [CrossRef] [PubMed]
4. Iversen, O.H. Kinetics of cellular proliferation and cell loss in human carcinomas. A discussion of methods available for in vivo studies. Eur. J. Cancer 1967, 3, 389–394. [CrossRef]
5. Refsum, S.B.; Berdal, P. Cell loss in malignant tumours in man. Eur. J. Cancer 1967, 3, 235–236. [CrossRef]
6. Sharon, N.; Lis, H. Lectins as cell recognition molecules. Science 1989, 246, 227–234. [CrossRef] [PubMed]
7. Hernandez, J.D.; Baum, L.G. Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 2002, 12, 127R–136R. [CrossRef] [PubMed]
8. Fuster, M.M.; Esko, J.D. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5, 526–542. [CrossRef] [PubMed]
9. Heusschen, R.; Griffioen, A.W.; Thijsen, V.L. Galectin-9 in tumor biology: A jack of multiple trades. Biochim. Biophys. Acta 2013, 1836, 177–185. [CrossRef] [PubMed]
10. Vladoiu, M.C.; Labrie, M.; St-Pierre, Y. Intracellular galectins in cancer cells: Potential new targets for therapy (Review). Int. J. Oncol. 2014, 44, 1001–1014. [PubMed]
11. Türeci, O.; Schmitt, H.; Fadle, N.; Pfleundschuh, M.; Sahin, U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease. J. Biol. Chem. 1997, 272, 6416–6422. [CrossRef] [PubMed]
12. Wada, J.; Kanwar, Y.S. Identification and characterization of galectin-9, a novel β-galactoside-binding mammalian lectin. J. Biol. Chem. 1997, 272, 6078–6086. [CrossRef] [PubMed]
13. Leal-Pinto, E.; Tao, W.; Rappaport, J.; Richardson, M.; Knorr, B.A.; Abramson, R.G. Molecular cloning and functional reconstitution of a urate transporter/channel. J. Biol. Chem. 1997, 272, 617–625. [PubMed]
14. Matsumoto, R.; Matsumoto, H.; Seki, M.; Hata, M.; Asano, Y.; Kanegasaki, S.; Stevens, R.L.; Hirashima, M. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 1998, 273, 16976–16984. [CrossRef] [PubMed]
15. Kuroda, J.; Yamamoto, M.; Nagoshi, H.; Kobayashi, T.; Sasaki, N.; Shimura, Y.; Horiike, S.; Kimura, S.; Yamauchi, A.; Hirashima, M., et al. Targeting activating transcription factor 3 by galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol. Cancer Res. 2010, 8, 994–1001. [CrossRef] [PubMed]
16. Kobayashi, T.; Kuroda, J.; Ashihara, E.; Oomizu, S.; Terui, Y.; Taniyama, A.; Adachi, S.; Takagi, T.; Yamamoto, M.; Sasaki, N.; et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. *Leukemia* 2010, 24, 843–850. [CrossRef] [PubMed]

17. Majno, G.; Joris, I. Apoptosis, oncosis, and necrosis. An overview of cell death. *Am. J. Pathol.* 1995, 146, 3–15. [PubMed]

18. Galluzzi, L.; Vitale, I.; Abrams, J.M.; Alnemri, E.S.; Baehrecke, E.H.; Blagosklonny, M.V.; Dawson, T.M.; Dawson, V.L.; El-Deiry, W.S.; Fulda, S.; et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. *Cell Death Differ.* 2012, 19, 107–120. [CrossRef] [PubMed]

19. McLuskey, K.; Mottram, J.C. Comparative structural analysis of the caspase family with other clan CD cysteine peptidases. *Biochem. J.* 2015, 466, 219–232. [CrossRef] [PubMed]

20. Delbridge, A.R.; Strasser, A. The Bcl-2 protein family, BH3-mimetics and cancer therapy. *Cell Death Differ.* 2015, 22, 1071–1080. [CrossRef] [PubMed]

21. Adams, J.M.; Cory, S. Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. *Curr. Opin. Immunol.* 2007, 19, 488–496. [CrossRef] [PubMed]

22. Willis, S.N.; Adams, J.M. Life in the balance: how BH3-only proteins induce apoptosis. *Curr. Opin. Cell Biol.* 2005, 17, 617–625. [CrossRef] [PubMed]

23. Guicciardi, M.E.; Gores, G.J. Life and death by death receptors. *FASEB J.* 2009, 23, 1625–1637. [CrossRef] [PubMed]

24. Boatright, K.M.; Salvesen, G.S. Mechanisms of caspase activation. *Curr. Opin. Cell Biol.* 2003, 15, 725–731. [CrossRef] [PubMed]

25. Green, D.R.; Kroemer, G. The pathophysiology of mitochondrial cell death. *Science* 2004, 305, 626–629. [CrossRef] [PubMed]

26. Danial, N.N.; Korsmeyer, S.J. Cell death: Critical control points. *Cell* 2004, 116, 205–219. [CrossRef] [PubMed]

27. Degterev, A.; Boyce, M.; Yuan, J. A decade of caspases. *Oncogene* 2003, 22, 8543–8567. [CrossRef] [PubMed]

28. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. *Cell* 2000, 100, 57–70. [CrossRef] [PubMed]

29. Lowe, S.W.; Cepero, E.; Evan, G. Intrinsic tumour suppression. *Nature* 2004, 432, 307–315. [CrossRef] [PubMed]

30. Helenius, A.; Aebl, M. Intracellular functions of N-linked glycans. *Science* 2001, 291, 2364–2369. [CrossRef] [PubMed]

31. Nairn, A.V.; York, W.S.; Harris, K.; Hall, E.M.; Pierce, J.M.; Moremen, K.W. Regulation of glycan structures in animal tissues: Transcript profiling of glycan-related genes. *J. Biol. Chem.* 2008, 283, 17298–17313. [CrossRef] [PubMed]

32. Lauc, G.; Pezer, M.; Rudan, I.; Campbell, H. Mechanisms of disease: the human N-glycome. *Biochim. Biophys. Acta* 2016, 1860, 1574–1582. [CrossRef] [PubMed]

33. Cha, J.; Goh, G.; Bard, F. Short O-GalNAc glycans: Regulation and role in tumor development and clinical perspectives. *Biochim. Biophys. Acta* 2016, 1860, 1623–1639. [CrossRef] [PubMed]

34. Gupta, G.; Surolia, A.; Sampathkumar, S.G. Lectin microarrays for glycomic analysis. *OMICS* 2010, 14, 419–436. [CrossRef] [PubMed]

35. Shatnyeva, O.M.; Kubarenko, A.V.; Weber, C.E.; Pappa, A.; Schwartz-Albiez, R.; Weber, A.N.; Krammer, P.H.; Lavrik, I.N. Modulation of the CD95-induced apoptosis: The role of CD95 N-glycosylation. *PLoS ONE* 2011, 6, e19927. [CrossRef] [PubMed]

36. Chartier, E.; Condé, C.; Zhang, J.; Deneubourg, L.; di Valentin, E.; Rahmouni, S.; Chariot, A.; Agostinis, P.; Pang, P.C.; Haslam, S.M.; et al. SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activity. *Leukemia* 2010, 24, 821–832. [CrossRef] [PubMed]

37. Moriwaki, K.; Noda, K.; Furukawa, Y.; Ohshima, K.; Uchiyama, A.; Nakagawa, T.; Taniguchi, N.; Daigo, Y.; Nakamura, Y.; Hayashi, N.; et al. Deficiency of GMDS leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling. *Gastroenterology* 2009, 137, 188–198. [CrossRef] [PubMed]
38. Moriwaki, K.; Shinzaki, S.; Miyoshi, E. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. *J. Biol. Chem.* 2011, 286, 43123–43133. [CrossRef] [PubMed]

39. Lichtenstein, R.G.; Rabinovich, G.A. Glycobiology of cell death: When glycans and lectins govern cell fate. *Cell Death Differ.* 2013, 20, 976–986. [CrossRef] [PubMed]

40. Matarrese, P.; Tinari, A.; Mormone, E.; Bianco, G.A.; Toscano, M.A.; Ascione, B.; Rabinovich, G.A.; Malorni, W. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. *J. Biol. Chem.* 2005, 280, 6969–6985. [CrossRef] [PubMed]

41. Fukumori, T.; Takenaka, Y.; Oka, N.; Yoshii, T.; Hogan, V.; Inohara, H.; Kanayama, H.O.; Kim, H.R.; Raz, A. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. *Cancer Res.* 2004, 64, 3376–3379. [CrossRef] [PubMed]

42. Mazurek, N.; Byrd, J.C.; Sun, Y.; Hafley, M.; Ramirez, K.; Burks, J.; Bresalier, R.S. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. *Cell Death Differ.* 2012, 19, 523–533. [CrossRef] [PubMed]

43. Brewer, C.F.; Miceli, M.C.; Baum, L.G. Clusters, bundles, arrays and lattices: Novel mechanisms for lectin-saccharide-mediated cellular interactions. *Curr. Opin. Struct. Biol.* 2002, 12, 616–623. [CrossRef]

44. Bacigalupo, M.L.; Manzi, M.; Rabinovich, G.A.; Troncoso, M.F. Hierarchical and selective roles of galectins in innate immunity and adaptive immunity. *Mol. Immunol.* 2011, 48, 670–677. [CrossRef] [PubMed]

45. Hirashima, M.; Ueno, M.; Kamiya, K.; Higuchi, S.; Matsumoto, R. Functional heterogeneity of human eosinophil chemotactic lymphokines. *Lymphokine Cytokine Res.* 1991, 10, 481–486. [PubMed]

46. Hirashima, M.; Ueno, M.; Higuchi, S.; Matsumoto, T.; Sakata, K.M.; Matsumoto, R.; Adachi, M. Establishment of a human T-cell line constitutively producing several eosinophil chemotactic lymphokines and their functional heterogeneity on eosinophils. *Lymphokine Cytokine Res.* 1992, 11, 331–338. [PubMed]

47. Matsushita, N.; Nishi, N.; Seki, M.; Matsumoto, R.; Kuwabara, I.; Liu, F.T.; Hata, Y.; Nakamura, T.; Hirashima, M. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. *J. Biol. Chem.* 2000, 275, 8355–8360. [CrossRef] [PubMed]

48. Lipkowitz, M.S.; Leal-Pinto, E.; Rappoport, J.Z.; Najfeld, V.; Abramson, R.G. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. *J. Clin. Investig.* 2001, 107, 1103–1115. [CrossRef] [PubMed]

49. Nagae, M.; Nishi, N.; Murata, T.; Usui, T.; Nakamura, T.; Wakatsuki, S.; Kato, R. Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. *J. Biol. Chem.* 2006, 281, 35884–35893. [PubMed]

50. Yoshida, H.; Teraoka, M.; Nishi, N.; Nakakita, S.; Nakamura, T.; Hirashima, M.; Kamitori, S. X-ray structures of human galectin-9 C-terminal domain in complexes with a biantennary oligosaccharide and sialyllactose. *J. Biol. Chem.* 2010, 285, 36969–36976. [CrossRef] [PubMed]

51. Bi, S.; Earl, L.A.; Jacobs, I.; Baum, L.G. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. *J. Biol. Chem.* 2008, 283, 12248–12258. [CrossRef] [PubMed]

52. Li, Y.; Feng, J.; Geng, S.; Geng, S.; Wei, H.; Chen, G.; Li, X.; Wang, L.; Wang, R.; Peng, H.; et al. The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. *Mol. Immunol.* 2011, 48, 670–677. [PubMed]

53. Nishi, N.; Itoh, A.; Fujiyama, A.; Yoshida, N.; Araya, S.; Hirashima, M.; Shoji, H.; Nakamura, T. Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. *FEBS Lett.* 2005, 579, 2058–2064. [CrossRef] [PubMed]

54. Sato, M.; Nishi, N.; Shoji, H.; Seki, M.; Hashidate, T.; Hirabayashi, J.; Kasai, K.; Hata, Y.; Suzuki, S.; Hirashima, M.; et al. Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. *Glycobiology* 2002, 12, 191–197. [CrossRef] [PubMed]

55. Matsumoto, R.; Hirashima, M.; Kita, H.; Gleich, G.J. Biological activities of ecalectin: A novel eosinophil-activating factor. *J. Immunol.* 2002, 168, 1961–1967. [CrossRef] [PubMed]

56. Earl, L.A.; Bi, S.; Baum, L.G. Galectin multimerization and lattice formation are regulated by linker region structure. *Glycobiology* 2011, 21, 6–12. [CrossRef] [PubMed]
57. Lahm, H.; Hoeﬂich, A.; Andre, S.; Sordat, B.; Kaltner, H.; Wolf, E.; Gabius, H.J. Gene expression of galectin-9/ecalectin, a potent eosinophil chemoattractant, and/or the insertional isoform in human colorectal carcinoma cell lines and detection of frame-shift mutations for protein sequence truncations in the second functional lectin domain. Int. J. Oncol. 2000, 17, 519–524. [PubMed]
58. Heusschen, R.; Freitag, N.; Tirado-González, I.; Barrientos, G.; Moschansky, P.; Muñoz-Fernández, R.; Leno-Durán, E.; Klapp, B.F.; Thijssen, V.L.; Blois, S.M. Profiling Lgals9 splice variant expression at the fetal-maternal interface: Implications in normal and pathological human pregnancy. Biol. Reprod. 2013, 88, 22. [CrossRef] [PubMed]
59. Hirashima, M.; Kashio, Y.; Nishi, N.; Yamauchi, A.; Imaizumi, T.A.; Kageshita, T.; Saita, N.; Nakamura, T. Galectin-9 in physiological and pathological conditions. Glycoconj. J. 2004, 19, 593–600. [CrossRef] [PubMed]
60. Chabot, S.; Kashio, Y.; Seki, M.; Shirato, Y.; Nakamura, K.; Nishi, N.; Nakamura, T.; Matsumoto, R.; Hirashima, M. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 2002, 12, 111–118. [CrossRef] [PubMed]
61. Oomizu, S.; Arikawa, T.; Niki, T.; Kadowaki, T.; Ueno, M.; Nishi, N.; Yamauchi, A.; Hattori, T.; Masaki, T.; Hirashima, M. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion. PLoS ONE 2012, 7, e48574. [CrossRef] [PubMed]
62. Keryer-Bibens, C.; Pioche-Durieu, C.; Villemant, C.; Souquère, S.; Nishi, N.; Hirashima, M.; Middeldorp, J.; Busson, P. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 2006, 6, 283. [CrossRef] [PubMed]
63. Mrizak, D.; Martin, N.; Barjon, C.; Jimenez-Pailhes, A.S.; Mustapha, R.; Niki, T.; Guigay, J.; Pancré, V.; de Launoit, Y.; Busson, P.; et al. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J. Natl Cancer Inst. 2015, 107, 363. [CrossRef] [PubMed]
64. Hirabayashi, J.; Hashidate, T.; Arata, Y.; Nishi, N.; Nakamura, T.; Hirashima, M.; Urashima, T.; Oka, T.; Futai, M.; Muller, W.E.; et al. Oligosaccharide speciﬁcity of galectins: A search by frontal afﬁnity chromatography. Biochim. Biophys. Acta 2002, 1572, 232–254. [CrossRef]
65. Sacchettini, J.C.; Baum, L.G.; Brewer, C.F. Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction. Biochemistry 2001, 40, 3009–3015. [CrossRef] [PubMed]
66. Collins, B.E.; Paulson, J.C. Cell surface biology mediated by low afﬁnity multivalent protein-glycan interactions. Curr. Opin. Chem. Biol. 2004, 8, 617–625. [CrossRef] [PubMed]
67. Garner, O.B.; Baum, L.G. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signaling. Biochem. Soc. Trans. 2008, 36, 1472–1477. [CrossRef] [PubMed]
68. Pace, K.E.; Lee, C.; Stewart, P.L.; Baum, L.G. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J. Immunol. 1999, 163, 3801–3811. [PubMed]
69. Belardi, B.; O’Donoghue, G.P.; Smith, A.W.; Groves, J.T.; Bertozzi, C.R. Investigating cell surface galectin-mediated cross-linking on glycoengineered cells. J. Am. Chem. Soc. 2012, 134, 9549–9552. [CrossRef] [PubMed]
70. Wada, J.; Ota, K.; Kumar, A.; Wallner, E.I.; Kanwar, Y.S. Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J. Clin. Investig. 1997, 99, 2452–2461. [CrossRef] [PubMed]
71. Tsuboi, Y.; Abe, H.; Nakagawa, R.; Oomizu, S.; Watanabe, K.; Nishi, N.; Nakamura, T.; Yamauchi, A.; Hirashima, M. Galectin-9 protects mice from the Shwartzman reaction by attracting prostaglandin E2-producing polymorphonuclear leukocytes. Clin. Immunol. 2007, 124, 221–233. [CrossRef] [PubMed]
72. Spitzenerberger, F.; Graessler, J.; Schroeder, H.E. Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie 2001, 83, 851–862. [CrossRef]
73. Thijssen, V.L.; Hulsmans, S.; Griffioen, A.W. The galectin profile of the endothelium: Altered expression and localization in activated and tumor endothelial cells. Am. J. Pathol. 2008, 172, 545–553. [CrossRef] [PubMed]
74. Asakura, H.; Kashio, Y.; Nakamura, K.; Seki, M.; Dai, S.; Shirato, Y.; Abedin, M.J.; Yoshida, N.; Nishi, N.; Imaizumi, T.; et al. Selective eosinophil adhesion to fibroblast via IFN-γ-induced galectin-9. J. Immunol. 2002, 169, 5912–5918. [CrossRef] [PubMed]
75. Zhang, Z.Y.; Dong, J.H.; Chen, Y.W.; Wang, X.Q.; Li, C.H.; Wang, J.; Wang, G.Q.; Li, H.L.; Wang, X.D. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 2012, 13, 2503–2509. [CrossRef] [PubMed]
76. Laderach, D.J.; Gentilini, L.D.; Giribaldi, L.; Delgado, V.C.; Nugnes, L.; Croci, D.O.; Al Nakouzi, N.; Sacca, P.; Casas, G.; Mazza, O.; et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. *Cancer Res.* 2013, 73, 86–96. [CrossRef] [PubMed]

77. Mayoral, M.A.; Mayoral, C.; Meneses, A.; Villalvazo, L.; Guzman, A.; Espinosa, B.; Ochoa, J.L.; Zenteno, E.; Guevara, J. Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. *Cancer Investig.* 2008, 26, 615–623. [CrossRef] [PubMed]

78. Cada, Z.; Smetana, K.; Lacina, L.; Plzáková, Z.; Stork, J.; Kaltner, H.; Russwurm, R.; Lensch, M.; André, S.; Gabius, H.J. Immunohistochemical fingerprinting of the network of seven adhesion/growth-regulatory lectins in human skin and detection of distinct tumour-associated alterations. *Folia Biol. (Praha)* 2009, 55, 145–152. [PubMed]

79. Kageshita, T.; Kashio, Y.; Yamauchi, A.; Seki, M.; Abedin, M.J.; Nishi, N.; Shoji, H.; Nakamura, T.; Ono, T.; Hirashima, M. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. *Int. J. Cancer* 2002, 99, 809–816. [CrossRef] [PubMed]

80. Chan, S.W.; Kallarakkal, T.G.; Abraham, M.T. Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers. *Asian Pac. J. Cancer Prev.* 2014, 15, 2145–2152. [CrossRef] [PubMed]

81. Terris, B.; Blaveri, E.; Crnogorac-Jurcevic, T.; Jones, M.; Missiaglia, E.; Ruszniewski, P.; Sauvanet, A.; Lemoine, N.R. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. *Am. J. Pathol.* 2002, 160, 1745–1754. [CrossRef]

82. Yang, J.; Zhu, L.; Cai, Y.; Suo, J.; Jin, J. Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer. *Int. J. Oncol.* 2014, 45, 1313–1320. [CrossRef] [PubMed]

83. Jiang, J.; Jin, M.S.; Kong, F.; Cao, D.; Ma, H.X.; Jia, Z.; Wang, Y.P.; Suo, J.; Cao, X. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. *PLoS ONE* 2013, 8, e81799. [CrossRef] [PubMed]

84. Kashio, Y.; Nakamura, K.; Abedin, M.J.; Seki, M.; Nishi, N.; Yoshida, N.; Nakamura, T.; Hirashima, M. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. *J. Immunol.* 2003, 170, 3631–3636. [CrossRef] [PubMed]

85. Zhu, C.; Anderson, A.C.; Schubart, A.; Xiong, H.; Imitola, J.; Khoury, S.J.; Zheng, X.X.; Strom, T.B.; Kuchroo, V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. *Nat. Immunol.* 2005, 6, 1245–1252. [CrossRef] [PubMed]

86. Monney, L.; Sabatos, C.A.; Gaglia, J.L.; Ryu, A.; Waldner, H.; Chernova, T.; Manning, S.; Greenfield, E.A.; Coyle, A.J.; Sobel, R.A.; et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. *Nature* 2002, 415, 536–541. [CrossRef] [PubMed]

87. Miao, E.A.; Leaf, I.A.; Treuting, P.M.; Mao, D.P.; Dors, M.; Sarkar, A.; Warren, S.E.; Wewers, M.D.; Aderem, A. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. *Nat. Immunol.* 2010, 11, 1136–1142. [CrossRef] [PubMed]

88. Vande Walle, L.; Lamkanfi, M. Pyroptosis. *Curr. Biol.* 2016, 26, R568–R572. [CrossRef] [PubMed]

89. Cookson, B.T.; Brennan, M.A. Pro-inflammatory programmed cell death. *Trends Microbiol.* 2001, 9, 113–114. [CrossRef]

90. Edgeworth, J.D.; Spencer, J.; Phalipon, A.; Griffin, G.E.; Sansonetti, P.J. Cytotoxicity and interleukin-1β processing following *Shigella flexneri* infection of human monocyte-derived dendritic cells. *Eur. J. Immunol.* 2002, 32, 1464–1471. [CrossRef]

91. Fink, S.L.; Bergsbaken, T.; Cookson, B.T. Anthrax lethal toxin and salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. *Proc. Natl Acad. Sci. USA* 2008, 105, 4312–4317. [CrossRef] [PubMed]

92. Cuesta, N.; Nhu, Q.M.; Zudaire, E.; Polumuri, S.; Cuttitta, F.; Vogel, S.N. IFN regulatory factor-2 regulates macrophage apoptosis through a STAT1/3- and caspase-1-dependent mechanism. *J. Immunol.* 2007, 178, 3602–3611. [CrossRef] [PubMed]

93. Sollberger, G.; Strittmatter, G.E.; Grossi, S.; Garstkiewicz, M.; Auf dem Keller, U.; French, L.E.; Beer, H.D. Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes. *J. Investig. Dermatol.* 2015, 135, 1395–1404. [CrossRef] [PubMed]
94. Wiersma, V.R.; de Bruyn, M.; van Ginkel, R.J.; Sigar, E.; Hirashima, M.; Niki, T.; Nishi, N.; Samplonius, D.F.; Helfrich, W.; Bremer, E. The glycogen-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. **J. Investig. Dermatol.** 2012, 132, 2302–2305. [CrossRef] [PubMed]

95. Fujita, K.; Iwama, H.; Sakamoto, T.; Okura, R.; Kobayashi, K.; Takano, J.; Katsura, A.; Tatsuta, M.; Maeda, E.; Mimura, S.; et al. Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. **Int. J. Oncol.** 2015, 46, 2419–2430. [CrossRef] [PubMed]

96. Kobayashi, K.; Morishita, A.; Iwama, H.; Fujita, K.; Okura, R.; Fujihara, S.; Yamashita, T.; Fujimori, T.; Kato, K.; Kamada, H.; et al. Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. **Oncol. Rep.** 2015, 34, 1761–1770. [CrossRef] [PubMed]

97. Tadokoro, T.; Morishita, A.; Fujihara, S.; Iwama, H.; Niki, T.; Fujita, K.; Akashi, E.; Mimura, S.; Oura, K.; Sakamoto, T.; et al. Galectin-9: An anticancer molecule for gallbladder carcinoma. **Int. J. Oncol.** 2016, 48, 1165–1174. [CrossRef] [PubMed]

98. Takano, J.; Morishita, A.; Fujihara, S.; Iwama, H.; Kokado, F.; Fujikawa, K.; Fujita, K.; Chiyo, T.; Tadokoro, T.; Sakamoto, T.; et al. Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. **Oncol. Rep.** 2016, 35, 851–860. [CrossRef] [PubMed]

99. Fujihara, S.; Mori, H.; Kobara, H.; Rafiq, K.; Niki, T.; Hirashima, M.; Masaki, T. Galectin-9 in cancer therapy. **Recent Pat. Endocr. Metab. Immune Drug Discov.** 2013, 7, 130–137. [CrossRef] [PubMed]

100. Seki, M.; Oomizu, S.; Sakata, K.M.; Sakata, A.; Arikawa, T.; Watanabe, K.; Ito, K.; Takeshita, K.; Niki, T.; Saita, N.; et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. **Clin. Immunol.** 2008, 127, 78–88. [CrossRef] [PubMed]

101. Mengshol, J.A.; Golden-Mason, L.; Arikawa, T.; Smith, M.; Niki, T.; McWilliams, R.; Randall, J.A.; McMahen, R.; Zimmerman, M.A.; Rangachari, M.; et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. **PLoS ONE** 2010, 5, e9504. [CrossRef]

102. Irie, A.; Yamauchi, A.; Kontani, K.; Kihara, M.; Liu, D.; Shirato, Y.; Seki, M.; Nishi, N.; Nakamura, T.; Yokomise, H.; et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. **Clin. Cancer Res.** 2005, 11, 2962–2968. [CrossRef] [PubMed]

103. Seki, M.; Sakata, K.M.; Oomizu, S.; Arikawa, T.; Sakata, A.; Ueno, M.; Nobumoto, A.; Niki, T.; Saita, N.; Ito, K.; et al. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. **Arthritis Rheum.** 2007, 56, 3968–3976. [CrossRef] [PubMed]

104. Chagan-Yasutan, H.; Saitoh, H.; Ashino, Y.; Arikawa, T.; Hirashima, M.; Li, S.; Usuzawa, M.; Oguma, S.; O Telan, E.F.; Obi, C.L.; et al. Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy. **Tohoku J. Exp. Med.** 2009, 218, 285–292. [CrossRef] [PubMed]

© 2017 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).